The presenter does not have any potential conflicts of interest to disclose

Similar documents
Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis

The association of the total cardiovascular risk and non-invasive markers of atherosclerosis with the extent of coronary artery disease

Tailored carotid artery stenting

Patient referral for elective coronary angiography: challenging the current strategy

PrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!!

Vascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

P. Paluszek, P. Pieniazek, P. Musialek, T. Przewlocki, L. Tekieli, A. Kablak-Ziembicka, K. Dzierwa, M. Hlawaty, M. Trystula, P.

Intima-Media Thickness

Landmesser U et al. Eur Heart J 2017; /eurheartj/ehx549

Invasive treatment for carotid fibromuscular dysplasia

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Joshua A. Beckman, MD. Brigham and Women s Hospital

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Which CVS risk reduction strategy fits better to carotid US findings?

Treatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery

Alma Mater Studiorum Università di Bologna

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION

The Impact of Smoking on Acute Ischemic Stroke

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Coronary artery disease (CAD) risk factors

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

PATIENTS AND METHODS:

Report For Center Created Gender D.O.B Page 1 Sean Breen HeartSmart IMT plus 3/29/2012 Male 11/26/1973 B C D E

MPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola

Epicardial fat volume as a predictor of coronary vulnerable plaques using cardiac computed tomography in the patients with zero calcium score

Diabetes and Occult Coronary Artery Disease

collaterals offset ischemia

Title for Paragraph Format Slide

C oronary artery disease (CAD) remains the main cause

The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent

How would you manage Ms. Gold

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.

Prevalence and Significance of Carotid Plaques in Patients With Coronary Atherosclerosis

UNITED STATES AIR FORCE AEROMEDICAL UPDATE AND REVIEW FOR AVIATORS WITH KNOWN CORONARY ARTERY DISEASE

2/20/2013. Why use imaging in CV prevention? Update on coronary CTA in 2013 Coronary CTA for 1 0 prevention: pros and cons Are we there yet?

The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease

Η Πυρηνική Καρδιολογία Το 2017 ΟΜΑΔΑ ΕΡΓΑΣΙΑΣ ΑΠΕΙΚΟΝΙΣΤΙΚΩΝ ΤΕΧΝΙΚΩΝ

Asian J. Exp. Sci., Vol. 27, No. 1, 2013; 67-72

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million life insurance

Atherothrombosis And Coronary Artery Disease

New Insight about FFR and IVUS MLA

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Simultaneous Acute ST Elevation Myocardial Infarction And Acute Left Subclavian Artery Thrombosis

FFR in Multivessel Disease

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

New Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008

Omics and coronary atherosclerosis

Piotr Musialek, MD DPhil. Jagiellonian University Dept. of Cardiac & Vascular Diseases John Paul II Hospital, Krakow, Poland

Carotid ecodoppler and transesophageal echocardiography: complementary methods for evaluation of atherosclerosis?

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Atherosclerosis Regression An Overview of Recent Findings & Issues

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Coronary Artery Calcium Scoring Mirvat Alasnag FACP, FRCP, FSCCT, FSCAI, FASE King Fahd Armed Forces Hospital, Jeddah. March 2017

Malmö Diet and Cancer Study incl. CV-cohort. Cardiovascular Endpoints

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58

MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million Life Insurance

7 th Munich Vascular Conference

Imaging in the Evaluation of Coronary Artery Disease and Abdominal Aortic Aneurysm

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

Current and Future Imaging Trends in Risk Stratification for CAD

BENEFIT APPLICATION BLUECARD/NATIONAL ACCOUNT ISSUES

Cover Page. The handle holds various files of this Leiden University dissertation

Coronary Artery Disease - Reporting and Data System (CAD-RADS)

LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:


CPORT E Trial. Atlantic C PORT

Patient characteristics Intervention Comparison Length of followup

PCSK9 Inhibitors and Modulators

Medical Policy. Medical Policy. MP Computed Tomography to Detect Coronary Artery Calcification

THE CARDIOVASCULAR RISK FACTORS PROFILE PREDISPOSING TO HEART ATTACKS IN YOUNG WOMEN

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Non-Selective Carotid Artery Ultrasound Screening in Patients Undergoing Coronary Artery Bypass Grafting: Is It Necessary?

Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine

Hidden coronary disease in carotid patients

Is there enough evidence for DAPT after endovascular intervention for PAOD?

Evaluation of Carotid Vessels and Vertebral Artery in Stroke Patients with Color Doppler Ultrasound and MR Angiography

Kavitha Yaddanapudi Stony brook University New York

Stroke prevention in asymptomatic carotid stenosis. ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ

Women and Ischemic Heart Disease Lessons Learned

Carotid Endarterectomy for Symptomatic Complete Occlusion of the Internal Carotid Artery

Carotid Ddisease, Carotid IMT and Risk of Stroke

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

Review of guidelines for management of dyslipidemia in diabetic patients

Carotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014

Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.

Atherosclerosis 220 (2012) Contents lists available at ScienceDirect. Atherosclerosis

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

CLINICAL OUTCOME Vs SURROGATE MARKER

Rikshospitalet, University of Oslo

Diagnostic and Prognostic Value of Coronary Ca Score

Disclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic

Management of stable CAD FFR guided therapy: the new gold standard

Transcription:

Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1, Tadeusz Przewłocki 1, Piotr Pieniążek 1, Jacek Gacoń 2, Agnieszka Rosławiecka 1, Łukasz Tekieli 1, Piotr Podolec 1 The presenter does not have any potential conflicts of interest to disclose 1 Jagiellonian University Medical College, Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland 2 E. Szczeklik Hospital, Department of Invasive Cardiology, Tarnow, Poland

OBJECTIVE The study aimed to assess the prevalence of concomitant to subclavian artery stenosis (SAS), significant stenoses in other major vascular locations, as well as possible associations between carotid intima-media thickness (CIMT) and internal carotid artery stenosis (ICAS) with cardiovascular (CV) risk.

STUDY ALGORYTHM 218 patients, in the mean age of 62.1±8.4 y with symptomatic SAS referred for PTA CVD - cardio-vascular death Baseline ultrasound evaluation of CIMT/ICAS degree MI - myocardial infarction IS - ischemic stroke Repeated CIMT/ICAS measurement in 108 randomly chosen patients The incidences of CV events were recorded mean follow-up time: 36.5±26 months during the follow-up period of 56.5±35 months Δ CIMT was calculated (the difference between CIMT final and CIMT initial ) Δ CIMT value was compared between patients with CV-event and those without CV-event in follow-up

Prevalence of classic risk factors for atherosclerosis in studied population (218 patients, 116 men) 218 173 (79%) 176 (81%) 60 (28%) 111 (51%) 0 smoking history diabetes arterial hypertension hypercholesterolemia

METHODS The prevalence of classic risk factors for atherosclerosis (diabetes, hyperlipidemia, arterial hypertension, smoking status) were recorded Coronary, renal and lower limb arteries (CAD/RAS/PAOD) were verified for presence of atherosclerotic lumen reductions of 50% by means of ultrasonography, CT or angiography Maximum CIMT of common, the bulb and internal carotid arteries were measured and expressed as a mean CIMT value Interpretation of mean CIMT change (Δ CIMT): Mean CIMT regression: any decrease in mean CIMT value at F-U No significant change: mean CIMT increase between 0.0 0.015mm/year Progression mean CIMT value increase > 0.016mm/year

Number of arterial territories with a significant stenosis in 218 subjects Involved territory N of patients CAD >50% 123 (53.4%) PAOD >50% 65 (29.8%) ICAS >50% 89 (40.1%) RAS >50% 25 (11.5%) 2 territories 55 ; (25%) 3 or 4 territories 34 ; (16%) isolated SAS 46 ; (21%) 1 territory 83 ; (38%) * Significant stenosis the presence of an artery lumen reduction of at least 50% in a given territory

CIMT quartiles and baseline subjects allocation depending on initial CIMT value and grade of ICA stenosis Median CIMT 1.38 mm 1st Q CIMT < 1.10 mm 2nd Q CIMT 1.11 1.38 3rd Q CIMT 1.39 1.70 4th Q CIMT > 1.71 CIMT <1mm 28 ; (12,8%) ICAS 50% 89 ; (40,8%) CIMT 1.0-1.3mm 50 ; (22,9%) CIMT >1.3 mm but ICAS <50% 51 ; (23,4%)

Initial CIMT value, incl. ICA atherosclerotic plaques, were significantly related to the presence of at least 50% lumen reduction in other arterial territories (Spearman co-efficient test) CAD presence CAD severity p=0.004 P=0.005 R = 0.231 R = 0.225 PAOD p=0.003 R = 0.311 RAS p=0.014 R = 0.194 The number of involved territories p<0.001 R = 0.573 Initial CIMT value, incl. ICA atherosclerotic plaques, occurred an independent marker of multi-territory arterial stenoses Relative risk Confidence interval p-value Initial CIMT value 1.16 1.05-1.28 0.005 ICA stenosis >50% 1.54 1.39-1.7 <0.001

LATE RESULTS CV events mean follow-up period of 56.5±35 months 218 patients after successful SAS PTA CV events 27 (12.4%) CV deaths 4 (1.8%) non-fatal MI 11 (5.0%) Non-fatal IS 12 (5.5%) 108 patients with repeated CIMT CV events 13 (12.0%) CV deaths 0 (0%) non-fatal MI 7 (6.5%) Non-fatal IS 6 (5.6% )

LATE RESULTS CV events mean follow-up period of 56.5±35 months 108 patients with CIMT follow-up Higher CIMT progression was noted in patient with CV-event, as compared to those with CV-event free follow-up (ΔCIMT: +0.199 ± 0.57mm vs. +0.008 ± 0.26mm, p=0.039) with CVevent without CVevent P-value Progression vs. no progression CIMT: progression n=53 10 (19%) 43 (81%) CIMT: no change n=10 1 (10%) 9 (90%) 0.032 CIMT: regression n=45 2 (7%) 43 (93%)

LATE RESULTS CV events mean follow-up period of 56.5±35 months 108 patients with CIMT follow-up CV-events were more prevalent in patients with initially more widespread atherosclerosis despite revascularization they underwent afterwards (mean number of involved territories: 1.8±1.1 vs. 1.3±1.1, p=0.042) Multivariate regression analysis identified 2 independent risk factors of CV events Relative risk CI 95% p-value Significant CAD 1.32 1.1-1.58 0.003 CIMT progression 1.22 1.02-1.46 0.033

CONCLUSIONS CIMT and ICAS stenosis are independently associated with multi-territory arterial stenoses Subjects with CIMT progression during mean 3-year F-U, suffered from CV events more often than whose with CIMT regression or stabilization Both significant CAD and CIMT progression were independently associated with a risk of future CV events in patients with symptomatic SAS